These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 28421459)

  • 1. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
    Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
    J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas.
    Richardson TE; Sathe AA; Kanchwala M; Jia G; Habib AA; Xiao G; Snuderl M; Xing C; Hatanpaa KJ
    J Neuropathol Exp Neurol; 2018 Jul; 77(7):542-548. PubMed ID: 29741737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.
    Hasselblatt M; Jaber M; Reuss D; Grauer O; Bibo A; Terwey S; Schick U; Ebel H; Niederstadt T; Stummer W; von Deimling A; Paulus W
    J Neuropathol Exp Neurol; 2018 Jun; 77(6):422-425. PubMed ID: 29444314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
    Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
    Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory.
    Kurdi M; Alkhotani A; Sabbagh A; Faizo E; Lary AI; Bamaga AK; Almansouri M; Hafiz B; Alsharif T; Baeesa S
    Oncol Res; 2024; 32(6):1037-1045. PubMed ID: 38827324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
    Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
    Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
    Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
    Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.
    Reuss DE; Kratz A; Sahm F; Capper D; Schrimpf D; Koelsche C; Hovestadt V; Bewerunge-Hudler M; Jones DT; Schittenhelm J; Mittelbronn M; Rushing E; Simon M; Westphal M; Unterberg A; Platten M; Paulus W; Reifenberger G; Tonn JC; Aldape K; Pfister SM; Korshunov A; Weller M; Herold-Mende C; Wick W; Brandner S; von Deimling A
    Acta Neuropathol; 2015 Sep; 130(3):407-17. PubMed ID: 26087904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
    Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated molecular characterization of IDH-mutant glioblastomas.
    Korshunov A; Casalini B; Chavez L; Hielscher T; Sill M; Ryzhova M; Sharma T; Schrimpf D; Stichel D; Capper D; Reuss DE; Sturm D; Absalyamova O; Golanov A; Lambo S; Bewerunge-Hudler M; Lichter P; Herold-Mende C; Wick W; Pfister SM; Kool M; Jones DTW; von Deimling A; Sahm F
    Neuropathol Appl Neurobiol; 2019 Feb; 45(2):108-118. PubMed ID: 30326163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.
    Wiestler B; Claus R; Hartlieb SA; Schliesser MG; Weiss EK; Hielscher T; Platten M; Dittmann LM; Meisner C; Felsberg J; Happold C; Simon M; Nikkhah G; Papsdorf K; Steinbach JP; Sabel M; Grimm C; Weichenhan D; Tews B; Reifenberger G; Capper D; Müller W; Plass C; Weller M; Wick W;
    Neuro Oncol; 2013 Aug; 15(8):1017-26. PubMed ID: 23595628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
    Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
    Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas.
    Cimino PJ; Holland EC
    Neuro Oncol; 2019 Jun; 21(6):819-821. PubMed ID: 30918961
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas.
    Wong QH; Li KK; Wang WW; Malta TM; Noushmehr H; Grabovska Y; Jones C; Chan AK; Kwan JS; Huang QJ; Wong GC; Li WC; Liu XZ; Chen H; Chan DT; Mao Y; Zhang ZY; Shi ZF; Ng HK
    Mod Pathol; 2021 Jul; 34(7):1245-1260. PubMed ID: 33692446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Signatures of Chromosomal Instability Correlate With Copy Number Variation Patterns and Patient Outcome in IDH-Mutant and IDH-Wildtype Astrocytomas.
    Richardson TE; Sathe AA; Xing C; Mirchia K; Viapiano MS; Snuderl M; Abdullah KG; Hatanpaa KJ; Walker JM
    J Neuropathol Exp Neurol; 2021 Mar; 80(4):354-365. PubMed ID: 33755138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas.
    Mirchia K; Snuderl M; Galbraith K; Hatanpaa KJ; Walker JM; Richardson TE
    Acta Neuropathol Commun; 2019 Jul; 7(1):121. PubMed ID: 31349875
    [No Abstract]   [Full Text] [Related]  

  • 18. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
    Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
    Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
    Ammendola S; Broggi G; Barresi V
    Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MR imaging phenotype correlates with extent of genome-wide copy number abundance in IDH mutant gliomas.
    Wu CC; Jain R; Neto L; Patel S; Poisson LM; Serrano J; Ng V; Patel SH; Placantonakis DG; Zagzag D; Golfinos J; Chi AS; Snuderl M
    Neuroradiology; 2019 Sep; 61(9):1023-1031. PubMed ID: 31134296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.